Hospital

Evidence-based guidelines support the safe and effective administration of Ig therapy in clinical practice.

National Adverse Drug Event Awareness Day was established to promote awareness, drive policy changes, and encourage health care professionals and patients to prioritize medication safety.

Pharmacists can help patients with diabetes save money.

Specialty distribution models, including limited drug distribution systems, ensure safe medication access but can create barriers for patients, making medically integrated pharmacies essential in coordinating care.

Jeff A. Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

In a debate at the 2025 APhA Annual Meeting, speakers highlighted GLP-1s’ advantages in stroke prevention and weight loss vs SGLT2s’ superiority in heart failure, CV death reduction, and renal protection.

Pharmacists can empower patient RSV vaccination through strategic communication and personalized care.

Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.

Contraceptive options have expanded since 1960, with pharmacists today playing a growing role as prescribers of contraception and studies showing the benefit of pharmacist-driven contraception clinics.

Sally Arif, PharmD, BCCP, discusses her presentation on the critical role of pharmacists in addressing health disparities by improving communication, fostering cultural competence, and promoting pharmacoequity.

Nakia Eldridge, PharmD, MBA, shares insights for health system and community pharmacists attending the 2025 APhA Annual Meeting & Exposition.

Patients with central nervous system (CNS) involvement achieved favorable outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.

Sjögren's disease is one of the most common chronic autoimmune diseases that affects 4 million individuals around the world.

This subset of heart failure requires unique therapeutic considerations.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

Health care professionals in the study found it challenging to manage the complexities of disordered eating in patients with type 1 diabetes alongside their other responsibilities.

Allogeneic stem cell transplant (allo-SCT) conditioning with busulfan/fludarabine with thiotepa and posttransplant cyclophosphamide induced improved 2-year progression-free survival and overall survival in patients with myelofibrosis, especially older adults.

BeeR is a bacterial protein from the family Verrucomicrobiota that influences cell shape and division.

As HIV treatment and prevention evolve, the use of long-acting injectables and their role in combating the HIV epidemic grows.

Prioritizing preventive measures for high-risk individuals would effectively address half of RSV hospitalizations.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

Ononogbu discusses research, health equity, and sickle cell advancements.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

As indicated by prior literature, a second dose of intravenous immunoglobulin (IVIG) in patients with Guillain-Barré syndrome increases serum immunoglobulin G levels without improving clinical outcomes.

Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.

Sharita Howe, PharmD, discusses her recent acknowledgement by MM+M, who acknowledged her as a part of the next wave of health care leaders in their recognition of 40 under 40 leaders in health care.

Pharmacists can optimize management of this condition with intravenous iron therapy guidance.